DC8A Stock Overview
A biopharmaceutical company, develops medicines based on its epigenetic regulator program. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
DURECT Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$1.61 |
| 52 Week Low | US$0.41 |
| Beta | 1.13 |
| 11 Month Change | -31.75% |
| 3 Month Change | -26.50% |
| 1 Year Change | 62.26% |
| 33 Year Change | -90.99% |
| 5 Year Change | -95.25% |
| Change since IPO | -99.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| DC8A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -21.8% | -6.1% | -0.2% |
| 1Y | 62.3% | -22.4% | 7.8% |
Return vs Industry: DC8A exceeded the German Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: DC8A exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| DC8A volatility | |
|---|---|
| DC8A Average Weekly Movement | 11.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DC8A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DC8A's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 48 | Jim Brown | www.durect.com |
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.
DURECT Corporation Fundamentals Summary
| DC8A fundamental statistics | |
|---|---|
| Market cap | €28.73m |
| Earnings (TTM) | -€16.12m |
| Revenue (TTM) | €8.12m |
3.5x
P/S Ratio-1.8x
P/E RatioIs DC8A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DC8A income statement (TTM) | |
|---|---|
| Revenue | US$8.59m |
| Cost of Revenue | US$31.17m |
| Gross Profit | -US$22.57m |
| Other Expenses | -US$5.50m |
| Earnings | -US$17.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.55 |
| Gross Margin | -262.66% |
| Net Profit Margin | -198.62% |
| Debt/Equity Ratio | 860.0% |
How did DC8A perform over the long term?
See historical performance and comparison